GA4GH 2019 leadership transitions. It is with great enthusiasm and gratitude that GA4GH Inc. announce several changes to the GA4GH leadership team: Heidi Rehm replaces David Haussler as Vice Chair; Moran Cabili and Tommi Nyrönen replace Ravi Pandya and Anthony Philippakis as DURI Work Stream Leads; Michael Baudis replaces Harindra Arachchi as Discovery Work Stream Lead; and Jean-Pierre Hubaux replaces Paul Flicek as Data Security Work Stream Lead. It is with great enthusiasm and gratitude that GA4GH Inc. announce several changes to the GA4GH leadership team. First, GA4GH Inc. would like to formally thank outgoing GA4GH Vice Chair David Haussler, Scientific Director of the University of California Santa Cruz Genomics Institute, for serving GA4GH from its infancy and providing invaluable vision and guidance to the data sharing community. David's contributions include planning and participating in the initial scoping meeting in 2013, co-authoring the White Paper that set the mandate for what became the Global Alliance for Genomics and Health, serving as co-chair of the Data Working Group from 2014 to 2017, and dedicating time, resources, and person power to the GA4GH Working Groups, Work Streams, and original Demonstration Projects - particularly the BRCA Challenge. David has passionately advocated for GA4GH in his many speaking engagements, bringing significant support and recognition to the organisation. Needless to say, David has been critical to its success and GA4GH Inc. look forward to continued engagement with him and his talented team. David is succeeded by Heidi Rehm, an institute member at the Broad Institute of MIT and Harvard and chief genomics officer at Massachusetts General Hospital. Heidi joins Kathryn North as a GA4GH Vice Chair. Heidi is by no means a newcomer to its community. Over the years she has served a variety of roles at GA4GH including founding co-lead of the former GA4GH Demonstration Project Matchmaker Exchange (MME), Driver Project Champion for both MME and ClinGen, Steering Committee Member, 5th Plenary Programme Committee Chair, and frequent contributor to a number of Work Streams, including Discovery, Genomic Knowledge Standards, and Clinical and Phenotypic Data Capture. In addition to these executive level changes, there have been a few transitions among GA4GH Work Streams Leads. Both Ravi Pandya (Microsoft) and Anthony Philippakis (Broad Institute) have stepped down as Co-Chairs of the Data Use and Researcher Identities Work Stream, to be replaced by Moran Cabili, Associate Director of Data Strategy and Alliances at Broad Institute's Data Science Platform, and Tommi Nyrönen, Head of the ELIXIR Finland Node, which is hosted at CSC-IT Center for Science Finland. Harindra Arachchi stepped down as Co-Lead of the Discovery Work Stream when he began a new role at the commercial company Editas Medicine in Cambridge, MA. Harindra is succeeded by Michael Baudis, a professor of bioinformatics (theoretical cytogenetics and oncogenomics) at the University of Zurich UZH and the Swiss Institute of Bioinformatics SIB. Finally, After more than four years of leadership, Paul Flicek, a senior scientist and team leader at EMBL-EBI, is stepping down as Co-Chair of the Data Security Work Stream. Paul has been an instrumental member of the GA4GH community, having contributed to the GA4GH White Paper and serving as the founding Co-Chair of the Security Working Group. GA4GH Inc. will continue to work with Paul's wider group at EMBL-EBI, in particular via Andy Yates' continued leadership in the Genome Knowledge Standards Work Stream. Paul is succeeded by Jean-Pierre Hubaux, Professor of Computer and Communication Science and Head of the Computer Communications and Applications Laboratory at EPFL in Lausanne, Switzerland. Jean-Pierre (JP) leads the Data Protection For Personalized Health project. He has co-organised the GenoPri event alongside GA4GH plenaries over the last couple of years, and GA4GH Inc. look forward to his practical and academic interest in security. GA4GH Inc. would like to thank every one of these individuals for their service to GA4GH over the past four years and into the future. Without passionate, dedicated contributors like them its organisation and its important work would not be possible. 11 Mar 2026 3 Mar 2026

Editas Medicine to present groundbreaking ldl-cholesterol-lowering CRISPR Gene Editing research at ESGCT Congress 2025. Posted: 1 week, 2 days ago / Oct. 6, 2025 1:12 p.m. UTC Editas Medicine to present CRISPR gene editing research at ESGCT Congress, highlighting LDL-cholesterol-lowering advancements. Quiver AI summary. Editas Medicine, Inc., a gene editing company, announced it will present at the European Society of Gene and Cell Therapy Congress in Seville, Spain, from October 7-10, 2025. The oral presentation, scheduled for October 9 at 5:00 p.m. CEST, will showcase their innovative CRISPR gene editing approach that lowers LDL cholesterol by upregulating LDLR in mice and non-human primates. Dr. Linda Burkly, the company's Executive Vice President and Chief Scientific Officer, will lead the presentation. Editas also plans to participate in investor conferences in October, including a fireside chat and a panel discussion on genome editing technologies. Presentation materials will be available on both the ESGCT and Editas websites. Potential positives. * Editas Medicine will present significant findings on LDL-cholesterol-lowering CRISPR gene editing at a major European conference, enhancing its visibility in the scientific community. * The company's participation in multiple investor conferences in October shows a commitment to engaging with investors and promoting its innovations. * The oral presentation by a high-level executive, Linda Burkly, Ph.D., underscores the expertise within the company and reinforces investor confidence in its leadership. * Editas Medicine's exclusive license agreements with prestigious institutions like the Broad Institute and Harvard University strengthen its position in the gene editing market. Potential negatives. * Details about the specific outcomes or advancements being presented at the ESGCT Congress could indicate a lack of substantial progress or results, which may raise questions about the effectiveness of the company's research efforts. * The presentation primarily focuses on animal models (mice and non-human primates), which might suggest that human applications are still far from realization, potentially leading to investor concerns about timelines for product development. What is the focus of Editas Medicine? Editas Medicine develops transformative gene editing medicines for serious diseases using CRISPR technology. When is Editas Medicine's presentation at the ESGCT Congress? The presentation is on October 9, 2025, at 5:00 p.m. CEST / 11:00 a.m. ET. Who will present at the ESGCT Congress? Linda Burkly, Ph.D, Executive Vice President and Chief Scientific Officer of Editas Medicine, will be the presenter. Where can I find the presentation after the ESGCT Congress? The presentation will be available in the "Posters & Presentations" section of Editas Medicine's website. What other conferences will Editas Medicine participate in? Editas Medicine will participate in the H.C. Wainwright Genetic Medicines Virtual Conference and the Chardan Genetic Medicines Conference in October. Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here. $EDIT insider trading activity. $EDIT insiders have traded $EDIT stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales. * GILMORE NEIL O'NEILL (CEO) has made 0 purchases and 2 sales selling 20,784 shares for an estimated $40,712. * LINDA BURKLY (EVP, CHIEF SCIENTIFIC OFFICER) has made 0 purchases and 3 sales selling 6,557 shares for an estimated $15,851. * AMY PARISON (SVP, Chief Financial Officer) has made 0 purchases and 3 sales selling 1,583 shares for an estimated $3,709. To track insider transactions, check out Quiver Quantitative's insider trading dashboard. $EDIT hedge fund activity. We have seen 75 institutional investors add shares of $EDIT stock to their portfolio, and 76 decrease their positions in their most recent quarter. * UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,600,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $5,720,000 * MILLENNIUM MANAGEMENT LLC added 1,590,955 shares (+557.3%) to their portfolio in Q2 2025, for an estimated $3,500,101 * MORGAN STANLEY removed 1,238,238 shares (-46.6%) from their portfolio in Q2 2025, for an estimated $2,724,123 * WOODLINE PARTNERS LP added 846,399 shares (+inf%) to their portfolio in Q2 2025, for an estimated $1,862,077 * NUVEEN, LLC added 633,230 shares (+200.0%) to their portfolio in Q2 2025, for an estimated $1,393,106 * UBS GROUP AG removed 586,015 shares (-48.2%) from their portfolio in Q2 2025, for an estimated $1,289,233 * CITADEL ADVISORS LLC added 522,025 shares (+447.4%) to their portfolio in Q2 2025, for an estimated $1,148,455 To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. $EDIT analyst ratings. Wall Street analysts have issued reports on $EDIT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings. * HC Wainwright & Co. issued a "Buy" rating on 08/15/2025 * Baird issued a "Outperform" rating on 05/13/2025 To track analyst ratings and price targets for $EDIT, check out Quiver Quantitative's $EDIT forecast page. $EDIT price targets. Multiple analysts have issued price targets for $EDIT recently. We have seen 4 analysts offer price targets for $EDIT in the last 6 months, with a median target of $4.5. * Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $5.0 on 09/05/2025 * Yanan Zhu from Wells Fargo set a target price of $4.0 on 09/03/2025 * Joel Beatty from Baird set a target price of $6.0 on 08/13/2025 Full release. CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) - Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming European Society of Gene and Cell Therapy (ESGCT) Congress, to be held October 7-10, 2025, in Seville, Spain. * European Society of Gene and Cell Therapy (ESGCT) Congress Title: A transformative LDL-cholesterol - lowering in vivo CRISPR gene editing medicine that functionally upregulates LDLR in mice and non-human primates Session Date and Time: Thursday, October 9, 5:00 p.m. CEST / 11:00 a.m. ET Session Title: 9A: Gene Editing II, Ex Vivo Applications Room: Parallel A Presenter: Linda Burkly, Ph.D, Executive Vice President and Chief Scientific Officer, Editas Medicine Final Abstract Number: OR069 Abstracts are available to registrants on the ESGCT website. The oral presentation will also be posted to the " Posters & Presentations " section of the Company's website at the time of the presentation and will remain accessible following the event. In addition, management will participate in the following upcoming investor conferences in October: * H.C. Wainwright Genetic Medicines Virtual Conference Format: Fireside Chat Date: Tuesday, October 14, 7:00 a.m. ET Location: Virtual * Chardan 9 [th] Annual Genetic Medicines Conference Panel Discussion: Genome Editing: Next Wave Technologies Date: Tuesday, October 21, 8:45 a.m. ET Location: New York, NY To access a live webcast of the presentations, please visit the "Investors" section of the Company's website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event. About Editas Medicine As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.